STOCK TITAN

Axsome Therapeutics, Inc - AXSM STOCK NEWS

Welcome to our dedicated page for Axsome Therapeutics news (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeutics stock.

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a leading biopharmaceutical company dedicated to developing innovative therapies for the treatment of central nervous system (CNS) disorders. Headquartered in New York City, Axsome's mission is to address unmet medical needs and improve the lives of patients suffering from CNS conditions.

The company's portfolio includes a mix of clinical-stage and research-stage product candidates, with a primary focus on CNS disorders such as depression, migraine, narcolepsy, and Alzheimer's disease. Axsome's pipeline features notable candidates like AXS-05 for major depressive disorder, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. These therapies are being developed to provide novel treatment options where current solutions are limited or inadequate.

Axsome manages its business as a single operating segment, emphasizing the development and delivery of groundbreaking CNS therapies. The company has made significant strides in advancing its clinical programs, with several candidates progressing through various stages of clinical trials. Recent achievements include positive data readouts from clinical studies and successful end-of-phase meetings with regulatory bodies, positioning Axsome closer to potential market approvals.

Financially, Axsome maintains a solid foundation through strategic collaborations, public offerings, and partnerships. These financial maneuvers have enabled sustained investment in research and development, essential for driving innovation and bringing new therapies to market.

Axsome's commitment to transforming the treatment landscape for CNS disorders is underscored by its active engagement with the medical community, participation in scientific conferences, and continuous updates to investors and stakeholders. The company’s proactive communication strategy ensures transparency and keeps all interested parties informed about ongoing developments.

For the latest updates, investors and media can reach out to Mark Jacobson, Chief Operating Officer, or Darren Opland, Director of Corporate Communications, at Axsome's headquarters in New York City. More information is available on the company’s website, www.axsome.com.

Rhea-AI Summary

Axsome Therapeutics (NASDAQ: AXSM) announced a virtual event on June 28, 2022, at 9:00 AM EDT to update investors on Sunosi® (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor. Sunosi is the first medication approved for improving wakefulness in adults with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA). The event will feature clinical insights from physician experts and covers commercial activities. The live webcast can be accessed through Axsome's website, with a replay available for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
conferences
-
-
Rhea-AI Summary

Axsome Therapeutics announced positive results from the GEMINI Phase 3 trial of AXS-05 for major depressive disorder (MDD). The treatment showed rapid and significant improvement in anhedonia symptoms, with a notable decrease on the MADRS anhedonia subscale compared to placebo (-9.70 vs -7.22 points; p=0.001). Improvements were observed from the first week of treatment. AXS-05 is a novel NMDA receptor antagonist and is under FDA review for MDD. These findings were presented at the ASCP 2022 Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
none
Rhea-AI Summary

Axsome Therapeutics announced positive long-term results from the EVOLVE trial of AXS-05, focusing on major depressive disorder (MDD). The study demonstrated significant, sustained improvements in depressive symptoms, anxiety, and overall functioning over 12 months. Key statistics include a 24.5-point improvement in the MADRS score and 68% remission rate at 12 months. AXS-05 showed a favorable safety profile, consistent with earlier trials. This presentation was part of the American Society of Clinical Psychopharmacology Annual Meeting, highlighting AXS-05's potential as an effective treatment for patients with treatment-resistant depression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
none
-
Rhea-AI Summary

AXS-05 (dextromethorphan-bupropion) has shown rapid, significant antidepressant efficacy compared to placebo, as highlighted in the GEMINI Phase 3 trial results published on May 30, 2022. The trial included 327 patients with moderate to severe major depressive disorder (MDD) and demonstrated a substantial reduction in depressive symptoms, particularly noted in the Montgomery-Åsberg Depression Rating Scale (MADRS). Notably, AXS-05 achieved a 39.5% remission rate at week 6. The drug maintained a favorable safety profile, with most adverse events being mild. A new drug application (NDA) is under FDA review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
-
Rhea-AI Summary

Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced the publication of results from its pivotal ASCEND Phase 2 clinical trial of AXS-05 (dextromethorphan-bupropion) for major depressive disorder (MDD). The study revealed that AXS-05 demonstrated statistically significant improvements in depressive symptoms compared to bupropion, with a mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) score of -13.7 vs. -8.8 points. Remission rates at week 6 were 46.5% for AXS-05 versus 16.2% for bupropion. The results support the ongoing NDA review by the FDA for AXS-05.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.3%
Tags
Rhea-AI Summary

Axsome Therapeutics has completed its acquisition of Sunosi from Jazz Pharmaceuticals, marking a significant shift towards becoming a commercial neuroscience company. Sunosi, a dual-acting dopamine and norepinephrine reuptake inhibitor, is FDA-approved for improving wakefulness in adults with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea. The drug boasts 96% insurance coverage, providing access to approximately 253 million lives. In clinical trials, Sunosi demonstrated significant efficacy in reducing daytime sleepiness and increasing wakefulness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.06%
Tags
-
Rhea-AI Summary

Axsome Therapeutics has completed the U.S. acquisition of Sunosi (solriamfetol) from Jazz Pharmaceuticals, enhancing its CNS product portfolio. Sunosi, approved by the FDA for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, boasts broad insurance coverage for 96% of commercial lives. The acquisition positions Axsome as a commercial neuroscience company, supporting patient access through comprehensive affordability programs. Clinical trials have shown significant efficacy for Sunosi, including up to 22% reduction in daytime sleepiness and increased wakefulness. Axsome plans further research into Sunosi.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.06%
Tags
-
Rhea-AI Summary

Jazz Pharmaceuticals has successfully completed the divestiture of Sunosi (solriamfetol) in the U.S. to Axsome Therapeutics for an upfront payment of $53 million. Jazz will receive royalties of high single-digit on U.S. net sales for current indications and mid-single-digit for future indications. This transaction allows Jazz to focus on strategic areas for sustainable growth, as stated by CEO Bruce Cozadd. The ex-U.S. transaction is expected to close within 60 days, enhancing Jazz's commitment to operational excellence and shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.06%
Tags
none
Rhea-AI Summary

Axsome Therapeutics (AXSM) reported financial results for Q1 2022, with R&D expenses at $12.6 million, down from $16.6 million in Q1 2021. General and administrative expenses surged to $25.7 million, up from $11.2 million. The company posted a net loss of $39.6 million, or $(1.03) per share, compared to a loss of $29.3 million, or $(0.78) per share, a year earlier. Axsome's NDA for AXS-05 in major depressive disorder is under Priority Review, with potential FDA action expected in Q2 2022. Key milestones for 2022 include AXS-07 NDA resubmission and AXS-14 NDA submission in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags

FAQ

What is the current stock price of Axsome Therapeutics (AXSM)?

The current stock price of Axsome Therapeutics (AXSM) is $90.73 as of December 20, 2024.

What is the market cap of Axsome Therapeutics (AXSM)?

The market cap of Axsome Therapeutics (AXSM) is approximately 4.3B.

What does Axsome Therapeutics, Inc. do?

Axsome Therapeutics develops novel therapies for central nervous system (CNS) disorders with limited treatment options.

Where is Axsome Therapeutics based?

Axsome Therapeutics is headquartered in New York City, at One World Trade Center, 22nd Floor.

What are some key products in Axsome's pipeline?

Key products include AXS-05 for major depressive disorder, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia.

What recent achievements has Axsome made?

Recent achievements include positive clinical trial data and successful regulatory meetings, advancing several pipeline candidates.

How does Axsome manage its business operations?

Axsome manages its business as one operating segment focused on developing and delivering CNS therapies.

How does Axsome maintain its financial health?

Axsome maintains its financial health through strategic collaborations, public offerings, and partnerships, ensuring sustained R&D investment.

Who are the key contacts for investors and media?

Investors can contact Mark Jacobson (COO), and media can contact Darren Opland (Director of Corporate Communications) at Axsome's headquarters.

What is the mission of Axsome Therapeutics?

Axsome's mission is to address unmet medical needs and improve the lives of patients suffering from CNS disorders.

What kind of disorders does Axsome focus on?

Axsome focuses on CNS disorders such as depression, migraine, narcolepsy, and Alzheimer's disease.

How can I stay updated on Axsome's latest news and developments?

You can stay updated by visiting Axsome's website or contacting their corporate communications team for the latest information.

Axsome Therapeutics, Inc

Nasdaq:AXSM

AXSM Rankings

AXSM Stock Data

4.27B
39.59M
16.68%
81.09%
15.86%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK